Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 5, 2003, Pages 403-406

  Mori, Kiyoshi ^a   Kondo, Tetsuro ^a   Kamiyama, Yukari ^a   Kano, Yasuhiko ^a   Tominaga, Keigo ^a  

^a TOCHIGI CANCER CENTER   (Japan)

Author keywords

Diarrhea; Hangeshashin to; Irinotecan; Kampo medicine; Non small cell lung cancer

Indexed keywords

ALPRAZOLAM; BAICALIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CODEINE PHOSPHATE; DIPHENHYDRAMINE; HANGE SHASHIN TO; IRINOTECAN; KAMPO; LOPERAMIDE; METHYLPREDNISOLONE; METOCLOPRAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HERBAL MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0038356729     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0585-0     Document Type: Article

References (20)

1. Abigerges D, Armand J-P, Chabot GG, Costa LD, Fadel E, Cote C, Herait D, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446
2. Asumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159
3. Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M, Kusunoki Y (1991) A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9:606
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of untreated non-small-cell lung cancer. J Clin Oncol 10:16
5. Gandia D, Abigerges D, Armand J-P, Chabot G, Costa LD, Forni MD (1993) CPT-11 induced cholinergic effects in cancer patients (letter). J Clin Oncol 11:196
6. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in mouse. Cancer Res 50:1715
7. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944
8. Masuda N, Fukuoka M, Kusunoki Y, Mastui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225
9. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308
10. Mori K, Saito Y, Tominaga K (1992) Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer. Am J Clin Oncol 15:344
11. Mori K, Hirose T, Machida S, Yokoyama K, Tominaga K (1997) A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 33:503
12. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T (1993) Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5
13. Negoro S, Fukuoka N, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly administration of CPT-11. J Natl Cancer Inst 83:1164
14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85
15. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907
16. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304
17. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194
18. Sakata Y, Suzuki H, Kamataki T (1994) Preventive effect of TJ-14, a Kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11) (in Japanese with English abstract). Jpn J Cancer Chemother 21:1241
19. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909
20. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of Kampo medicine and baicaline against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978